The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.
The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.
[EN] THE USE OF MURAMYLPEPTIDES IN THE TREATMENT OF MYELOSUPPRESSED OR OTHERWISE IMMUNOCOMPROMISED STATES<br/>[FR] EMPLOI DE PEPTIDES DU TYPE MURAMYLPEPTIDES POUR LE TRAITEMENT DE TROUBLES DE MYELOSUPPRESSION OU D'AUTRES ETATS AFFECTANT L'IMMUNITE
申请人:PEPTECH (UK) LIMITED
公开号:WO1998009989A1
公开(公告)日:1998-03-12
(EN) The use of a muramyl peptide compound in the preparation of an agent for the alleviation of immunosuppression is disclosed.(FR) L'invention porte sur l'emploi de composés de peptides de type muramyle pour la préparation d'un agent atténuant l'immunosuppression.